Fig. 3: Verteporfin in combination with combretastatin more effectively inhibits vasculature in transgenic zebrafish (Tg, fli:eGFP) embryos.
From: A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature
The zebrafish embryos at 8-hrs post fertilization were treated with drugs for 48 hrs. A Healthy zebrafish embryo taken at 8× magnification. Intersegmental vessel (ISV) phenotypes in a sectional view of: B DMSO; C CA4, 5 nM; D V, verteporfin, 250 nM; E V + CA4. F Graphical summary showing the ISV disruption ratio of B–E. Data are expressed as mean ± SEM, n = 5 embryos. G, H RT-qPCR analysis of vascular endothelial growth factor A (VEGFA, an angiogenesis gene) and VEGF receptor kdr in zebrafish embryos after treatments. Data are expressed as mean ± SEM, n = 4 embryos. *P < 0.05, **P < 0.01, ****P < 0.0001.
